Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1199-1205

  Courage, C ^a   Snowden, R ^a   Gescher, A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

A549 cells; Cell cycle; Cytostasis; Protein kinase C; Staurosporine

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; CELL DNA; LACTATE DEHYDROGENASE; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; STAUROSPORINE DERIVATIVE;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0029851176     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.517     Document Type: Article

References (23)

1. ABE K, YOSHIDA M, USUI T, HORINOUCHI S AND BEPPU T. (1991). Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp. Cell Res., 192, 122-127.
2. AKINAGA S, GOMI K, MORIMOTO M, TAMAOKI T AND OKABE M (1991). Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51, 4888-4892.
3. AKINAGA S, NOMURA K, GOMI K AND OKABE M. (1993). Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. J. Antibiotics, 46, 1767-1771.
4. AKINAGA S, NOMURA K, GOMI K AND OKABE M. (1994). Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol., 33, 273-280.
5. BLOBE GC, SACHS CW, KHAN WA, FABBRO D, STABEL S, WETSEL WC, OBEID LM, FINE RL AND HANNUN YA. (1993). Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKCα. J. Biol. Chem., 268, 658 - 664.
6. COURAGE C, BUDWORTH J AND GESCHER A. (1995). Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br. J. Cancer, 71, 697-704.
7. CRISSMAN HA, GADBOIS DM, TOBEY RA AND BRADBURY EM. (1991). Transformed mammalian cells are deficiant in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc. Natl Acad. Sci. USA, 88, 7580 - 7584.
8. DAVIS PD, ELLIOTT L, HARRIS W, HURST SA, KEECH E, KUMAR H, LAWTON G, NIXON JS AND WILKINSON SE. (1992). Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J. Med. Chem., 35, 994-1001.
9. GADBOIS DM, HAMAGUCHI JR, SWANK RA AND BRADBURY EM. (1992). Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun., 184, 80-85.
10. GONG J, TRAGANOS F AND DARZYNKIEWICZ. (1994). Staurosporine blocks cell cycle progression through G1 between the cyclin D and cyclin E restriction points. Cancer Res., 54, 3136-3139.
11. HENNIPMAN A, VAN OIRSCHOT BA, SMITS J, RIJKSEN G AND STAAL GE. (1989). Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res., 49, 516-521.
12. IKEGAMI Y, YANO S AND NAKAO K. (1996). Antitumor effect of CGP 41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn. J. Pharmacol., 70, 65-72.
13. KAWAKAMI K, FUTAMI H, TAKAHARA J AND YAMAGUCHI K. (1996). UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun., 219, 778-783.
14. MEYER T, REGENASS U, FABBRO D, ALTERI E, RÖSEL J, MÜLLER M, CARAVATTI G AND MATTER A. (1989). A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumour activity. Int. J. Cancer. 43, 851-856.
15. NORBURY C AND NURSE P. (1992). Animal cell cycles and their controls. Annu. Rev. Biochem., 61, 441-470.
16. O'BRIAN CA AND WARD NE. (1989). Biology of the protein kinase C family. Cancer Metast. Rev., 8, 199-214.
17. POWIS G. (1992). Signalling targets for anticancer drug development. Trends Pharmacol. Sci., 12, 188-194.
18. SEYNAEVE CM, STETLER-STEVENSON M, SEBERS S, KAUR G, SAUSVILLE EA AND WORLAND PJ. (1993). Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53, 2081-2086.
19. STANWELL C, GESCHER A, BRADSHAW TD AND PETTIT GR (1994). The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int. J. Cancer. 56, 585-592.
20. TAMAOKI T AND NAKANO H. (1990). Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology. 8, 732-735.
21. TOULLEC D, PIANETTI P, COSTE H, BELLEVERGUE P, GRAND-PERRET T, AJAKANE M, BAUDET V, BOISSIN P, BOURSIER E, LORIOLLE F, DUHAMEL L, CHARON D AND KIRILOVSKY J. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266, 15771-15781.
22. TRINKS U, BUCHDUNGER E, FURET P, KUMP W, METT W, MEYER T, MÜLLER M, REGENASS U, RIHS G, LYDON N AND TRAXLER P. (1994). Dianilinophthalimides: Potent and selective, ATP-competitive inhibitors of the EGF receptor protein tyrosine kinase. J. Med. Chem., 37, 1015-1027.
23. UTZ I, HOFER S, REGENASS U, HILBE W, THALER W, GRUNICKE H AND HOFMANN J. (1994). The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer. 57, 104-110.